Literature DB >> 3081250

Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives.

S Sone, G Lopez-Berestein, I J Fidler.   

Abstract

We investigated whether human peripheral blood monocytes isolated by centrifugal elutriation from healthy donors could be activated to become tumoricidal and release tumor cytolytic factor (TCF) subsequent to incubation with recombinant human interferon-gamma (r-IFN-gamma) or a derivative of muramyl dipeptide (nor-MDP), or both. Blood monocytes incubated in endotoxin-free medium containing up to 1000 U/ml of r-IFN-gamma or in medium containing less than 1 microgram/ml of nor MDP were not activated to lyse radiolabeled allogeneic human tumor cells. In contrast, the incubation of monocytes with various dose combinations of r-IFN-gamma and nor-MDP generated significant direct cytotoxic activity as well as production of TCF. Preincubation of the r-IFN-gamma and nor-MDP mixture with polymyxin B did not inhibit the synergism, thus ruling out the possibility that the process was due to endotoxin contamination. TCF harvested from monocyte culture supernatants was cytolytic against five allogeneic tumor targets, but not against a nontumorigenic cell line. Collectively, the data demonstrate that r-IFN-gamma can prime human blood monocytes to allow their activation by synthetic nor-MDP.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081250     DOI: 10.1007/bf00199855

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  49 in total

1.  Macrophage activation for tumor cytotoxicity: tumoricidal activity by macrophages from C3H/HeJ mice requires at least two activation stimuli.

Authors:  L P Ruco; M S Meltzer
Journal:  Cell Immunol       Date:  1978-11       Impact factor: 4.868

2.  Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.

Authors:  R Cailleau; M Olivé; Q V Cruciger
Journal:  In Vitro       Date:  1978-11

3.  Principles of blood separation and component extraction in a disposable continuous-flow single-stage channel.

Authors:  J P Hester; R M Kellogg; A P Mulzet; V R Kruger; K B McCredie; E J Freireich
Journal:  Blood       Date:  1979-07       Impact factor: 22.113

4.  Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes.

Authors:  S Sone; S Mutsuura; M Ogawara; E Tsubura
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

5.  Similarities of murine gamma interferon and the lymphokine that renders macrophages cytotoxic.

Authors:  W J Kleinschmidt; R M Schultz
Journal:  J Interferon Res       Date:  1982

6.  T-cell hybridoma production of macrophage activation factor (MAF) I. Separation of MAF from interferon gamma.

Authors:  T L Ratliff; D L Thomasson; R E McCool; W J Catalona
Journal:  J Reticuloendothel Soc       Date:  1982-05

7.  Recombinant interferon-gamma increases HLA-DR synthesis and expression.

Authors:  T Y Basham; T C Merigan
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

8.  Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma.

Authors:  J L Pace; S W Russell; R D Schreiber; A Altman; D H Katz
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

9.  Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing.

Authors:  J L Pace; S W Russell; B A Torres; H M Johnson; P W Gray
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

10.  Biological and antigenic similarities of murine interferon-gamma and macrophage-activating factor.

Authors:  L P Svedersky; C V Benton; W H Berger; E Rinderknecht; R N Harkins; M A Palladino
Journal:  J Exp Med       Date:  1984-03-01       Impact factor: 14.307

View more
  7 in total

1.  The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis.

Authors:  G A Rook; J Taverne; C Leveton; J Steele
Journal:  Immunology       Date:  1987-10       Impact factor: 7.397

2.  Role of interferon gamma and tumour necrosis factor alpha in monocyte-mediated cytostasis and cytotoxicity against a human histiocytic lymphoma cell line.

Authors:  A A van de Loosdrecht; G J Ossenkoppele; R H Beelen; M G Broekhoven; M M Langenhuijsen
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Destruction of tumor cells by monokines released from activated human blood monocytes: evidence for parallel and additive effects of IL-1 and TNF.

Authors:  Y Ichinose; J Y Tsao; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Enhanced human monocyte cytotoxicity by platelet-activating factor.

Authors:  F H Valone; R Philip; R J Debs
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

5.  Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro.

Authors:  A Thanhäuser; A Böhle; H D Flad; M Ernst; T Mattern; A J Ulmer
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

6.  Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages.

Authors:  T Utsugi; A Nii; D Fan; C C Pak; Y Denkins; P van Hoogevest; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF.

Authors:  S T Malik; D Martin; I Hart; F Balkwill
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.